

# Hepatobiliary and Pancreas Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart



■ Open to Accrual  
 ■ Low Accruing  
 ■ Pending Activation/Suspended

# Hepatocellular

LOCOREGIONAL	FIRST LINE	SECOND LINE	THIRD LINE
<p><b><u>UCI 19-49</u></b> Cabo + Ipi/Nivo + TACE</p> <p>Coord: H. Nguyen Accrual: 17/35</p>	<p><b><u>UCI 22-106</u></b> STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab</p> <p>Coord: H. Nguyen Accrual: 5/10</p>		
<p><b><u>UCI 23-75/ROUTE 90</u></b> Eye90 microspheres</p> <p>Coord: M. Duron Accrual: 0/15</p>	<p><b><u>UCI 22-211</u></b> MED1572 (IgG1 mAb) ± Bev ± Lenvatinib Slot request required Coord: C. Kang Accrual: 2/8</p>	<p><b><u>UCI 23-58</u></b> Livmoniplimab + Budigalimab or Lenvatinib or Sorafenib * Must never have received a TKI Coord: H. Nguyen Accrual: 0/10</p>	
	<p><b><u>UCI 23-104</u></b> Livmoniplimab + Budigalimab Atezolizumab + Bevacizumab Tremelimumab + Durvalumab</p> <p>Coord: H. Nguyen Accrual: 1/7</p>	<p><b><u>UCI 16-94</u></b> TATE + Nivolumab (includes gastric/GEJ)</p> <p>Coord: M. Duron Accrual: 26/40</p>	
	<p><b><u>UCI 23-86</u></b> Atezolizumab ± Bevacizumab (Child-Pugh B7 and B8)</p> <p>Coord: M. Duron Accrual: 0/10</p>	<p><b><u>UCI 23-24</u></b> HAI SD-101 + Pembrolizumab or Nivolumab</p> <p>Budget pending</p>	
		<p><b><u>UCI 23-215</u></b> AZD5851 (GPC3 Autologous CAR-T)</p> <p>Budget pending</p>	

## SYSTEMIC + OPERATIVE

### EA2197/OPT-IN

Gemcitabine + Cisplatin: Neo  
+ Adjuvant or Adjuvant only  
Incidental gallbladder

Coord: J. Balague  
Accrual: 0/10

### ETCTN 10608

Gemcitabine + Cisplatin +  
Durva Neo/Adjuvant for high-  
risk resectable ICC

IRB and PRMC pending

## FIRST LINE

### UCI 22-212

(includes Ampullary)

Durvalumab + any  
gemcitabine-based regimen

Coord: H. Nguyen  
Accrual: 4/8

### UCI 22-211

MED1572 (IgG1 mAb) or  
AZD2936 (TIGIT) ±  
gemcitabine and cisplatin

Slot request required

Coord: C. Kang  
Accrual: 2/8

Open to Accrual

Low Accruing

Pending Activation/Suspended

## SECOND LINE+

### ETCTN-10276

M3814 ± Avelumab +  
Hypofraction Radiation

Coord: H. Nguyen  
Accrual: 1/5

## SECOND LINE+ (INTRAHEPATIC)

### UCI 23-24

HAI SD-101 + Pembro or Nivo

Liver dominant ICC

Budget pending



■ Open to Accrual  
 ■ Low Accruing  
 ■ Pending Activation/Suspended

**PERIOPERATIVE**

**A021806**  
 Neo/adjuvant vs adjuvant  
 mFOLFIRINOX  
 Coord: J. Balangué  
 Accrual: 0/15

**UCI 22-75**  
 ELI-002 7P (oncolytic virus)  
 (KRAS Local testing)  
 Within 6 months of resection  
 or last adjuvant treatment  
 Coord: M. Duron  
 Accrual: 2/7

**BORDERLINE/  
 LOCALLY ADVANCED**

**ETCTN-10366**  
 M3814 (Peposertib) + radiation  
 therapy  
 Coord: H. Nguyen  
 Accrual: 4/8

**ETCTN-10464**  
 Olaparib with Durvalumab +  
 radiation therapy  
 Coord: H. Nguyen  
 Accrual: 0/5

**UCI 23-134**  
 Padeliporfin Vascular targeted  
 photodynamic therapy  
 Pending RA sign off

**FIRST LINE LA/METASTATIC**

**S2001**  
 Olaparib +/- Pembrolizumab (BRCA  
 1/2, STABLE DISEASE)  
 Coord: J. Balangué  
 Accrual: 2/4

**UCI 23-200**  
 AZD0901 (CLND18 ADC) with  
 NAL-IRI or Gemcitabine  
*Investigator discretion*  
 Pending Budget and CTA

**SECOND LINE**

**ETCTN 10522**  
 CA4948 + gemcitabine + nab-  
 paclitaxel  
 Coord: H. Nguyen  
 Accrual: 3/4  
 Suspended for MTD

**A022106**  
 Nab-paclitaxel + Gemcitabine ±  
 Cisplatin  
*BRCA1/2 or PALB2  
 PD on 1L FOLFIRINOX*  
 Coord: J. Balangué  
 Accrual: 0/3

**RECURRENT METASTATIC**

**Review Biomarker Based  
 Solid Tumors Pages 6 and 7**



**ADJUVANT**

S2104  
Capecitabine + Temozolomide  
vs observation  
  
Pancreatic NET Ki67 > 3%  
  
Coord: J. Balangué  
Accrual: 0/2

Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

## HER2

### UCI 20-67

DF1001 +/- nivo

Coord: M. Nguyen  
Accrual: 18/20

### UCI 23-66

BI 1810631 (HER2 Inhibitor)

Coord: C. Smith  
Accrual: 0/5

## TISSUE FACTOR

### UCI 21-146

MRG004A (TF ADC)

Coord: M. Duron  
Accrual: 5/11

## KRAS/NRAS

### UCI 21-53

LY3537982 (KRAS G12C Inhibitor)

Coord: J. Choe  
Accrual: 6/8

### 22-87

RMC-6236 (KRAS Inhibitor)

Pancreatic KRAS G12 and other RAS-type

Coord: C. Kang  
Accrual: 14/20

## INHERITED MUTATIONS

### ETCTN-10528

Novobiocin (POLθ)

Coord: H. Nguyen  
Pending SIV

## EGFR

### UCI 22-171

EGFR TriNKET +/- Nivolumab (Central testing)

Coord: M. Nguyen  
Accrual: 3/15

Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

Open to Accrual

Low Accruing

Pending Activation/Suspended

CLAUDIN 18.2

UCI 22-51  
ASP2138 (CLDN18.2)

Pancreatic and  
Gastric/GEJ

Coord: J. Balanguie  
Accrual: 2/10

EpCAM

UCI 23-85  
BA3182 (CAB T-cell:  
EpCAM)

All solid tumors (central  
EPCAM testing)

Pending CTSD testing

B7-H6

UCI 22-221  
BiTe of B7-H6

(Central B7-H6 testing)  
HCC and Pancreatic  
(also NSCLC, HNSCC,  
CRC, and gastric)

Coord: P. Yang  
Accrual: 3/12



Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

**UCI 22-26**

CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: J. Balague  
Accrual: 7/12

**UCI 23-07**

P-MUC1C-ALLO1 (CAR-T Cell)

Coord: J. Miranda  
Accrual: 0/5

**UCI 22-37**

TACH101 (KDM4C inhibitor)

Phase 1: all solid tumors

Coord: A. Luna  
Accrual: 5/10



## BLOOD COLLECTION

### UCI 21-124

ctDNA collection during HBP workup

Coord: J. Balangué  
Accrual: 14/15

### UCI 23-10/PRECEDE

(Blood collection for early detection of pancreatic cancer)

Pending budget/contract

### UCI 20-101

(Biospecimen Collection for patients planned to start IO treatment)

Coord: J. Koff  
Accrual: 53/80